Last reviewed · How we verify

NCT03757000

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

Status unknown Phase 1 Last updated 10 December 2018
What this trial tests

Phase 1 trial testing YY-20394 in B-cell Lymphoma Recurrent in 42 participants. Status unknown.

Timeline
25 December 2017
Primary endpoint
30 March 2019
30 May 2019

Quick facts

Lead sponsorShanghai YingLi Pharmaceutical Co. Ltd.
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment42
Start date25 December 2017
Primary completion30 March 2019
Estimated completion30 May 2019
Sites3 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Shanghai YingLi Pharmaceutical Co. Ltd. — full company profile →

Who can join

18 and older, any sex, with B-cell Lymphoma Recurrent or B-cell Chronic Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with relapse or refractory B cell malignant hematological tumor.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.
    Jiang N, Dai Q, Su X, Fu J, et al · · 2020 · cited 419× · PMID 32333246 · DOI 10.1007/s11033-020-05435-1
  2. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.
    Mishra R, Patel H, Alanazi S, Kilroy MK, et al · · 2021 · cited 207× · PMID 33801659 · DOI 10.3390/ijms22073464
  3. Tumor-Associated Macrophages: A Potential Target for Cancer Therapy.
    Tan Y, Wang M, Zhang Y, Ge S, et al · · 2021 · cited 96× · PMID 34178692 · DOI 10.3389/fonc.2021.693517
  4. New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
    Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071
  5. Small-molecule agents for cancer immunotherapy.
    Wang F, Fu K, Wang Y, Pan C, et al · · 2024 · cited 41× · PMID 38486980 · DOI 10.1016/j.apsb.2023.12.010
  6. Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.
    Miao Y, Medeiros LJ, Xu-Monette ZY, Li J, et al · · 2019 · cited 39× · PMID 30881917 · DOI 10.3389/fonc.2019.00107
  7. Phase 1 clinical trial of the PI3Kδ inhibitor YY-20394 in patients with B-cell hematological malignancies.
    Jiang B, Qi J, Song Y, Li Z, et al · · 2021 · cited 22× · PMID 34425850 · DOI 10.1186/s13045-021-01140-z
  8. Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL.
    Guarente V, Sportoletti P. · · 2021 · cited 15× · PMID 33805745 · DOI 10.3390/cancers13061280

Verify or expand the search:

Other trials of YY-20394

Trials testing the same drug.

Other recruiting trials for B-cell Lymphoma Recurrent

Currently open trials in the same condition.

Other Shanghai YingLi Pharmaceutical Co. Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03757000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing